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Abstract
Background: Aberrant activation NF-kappaB has been proposed as a mechanism of drug resistance in
pancreatic cancer. Recently, inhibition of glycogen synthase kinase-3 has been shown to exert anti-tumor
effects on pancreatic cancer cells by suppressing NF-kappaB. Consequently, we investigated whether
inhibition of GSK-3 sensitizes pancreatic cancer cells to the chemotherapeutic agent gemcitabine.
Methods: GSK-3 inhibition was achieved using the pharmacological agent AR-A014418 or siRNA against
GSK-3 alpha and beta isoforms. Cytotoxicity was measured using a Sulphorhodamine B assay and
clonogenic survival following exposure of six different pancreatic cancer cell lines to a range of doses of
either gemcitabine, AR-A014418 or both for 24, 48 and 72 h. We measured protein expression levels by
immunoblotting. Basal and TNF-alpha induced activity of NF-kappaB was assessed using a luciferase
reporter assay in the presence or absence of GSK-3 inhibition.
Results: GSK-3 inhibition reduced both basal and TNF-alpha induced NF-kappaB luciferase activity.
Knockdown of GSK-3 beta reduced nuclear factor kappa B luciferase activity to a greater extent than GSK-
3 alpha, and the greatest effect was seen with dual knockdown of both GSK-3 isoforms. GSK-3 inhibition
also resulted in reduction of the NF-kappaB target proteins XIAP, Bcl-XL, and cyclin D1, associated with
growth inhibition and decreased clonogenic survival. In all cell lines, treatment with either AR-A014418,
or gemcitabine led to growth inhibition in a dose- and time-dependent manner. However, with the
exception of  PANC-1 where drug synergy occurred with some dose schedules, the inhibitory effect of
combined drug treatment was additive, sub-additive, or even antagonistic.
Conclusion: GSK-3 inhibition has anticancer effects against pancreatic cancer cells with a range of genetic
backgrounds associated with disruption of NF-kappaB, but does not significantly sensitize these cells to the
standard chemotherapy agent gemcitabine. This lack of synergy might be context or cell line dependent,
but could also be explained on the basis that although NF-kappaB is an important mediator of pancreatic
cancer cell survival, it plays a minor role in gemcitabine resistance. Further work is needed to understand
the mechanisms of this effect, including the potential for rational combination of GSK3 inhibitors with
other targeted agents for the treatment of pancreatic cancer.
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Background
Surgery is the only curative treatment for pancreatic can-
cer, but the majority of patients have metastatic disease or
an unresectable tumor at diagnosis [1,2]. Due to the poor
response to chemo- and radiation therapies, the disease is
highly lethal [2]. Gemcitabine (difluorodeoxycytidine) is
the most active chemotherapy agent used for the treat-
ment of pancreatic cancer [3]. It is an analog of deoxycyti-
dine, that gets incorporated into double stranded DNA
during S phase, resulting in inhibition of DNA synthesis,
arrest of the cell cycle progression, and induction of apop-
tosis [4]. However, due to pre-existing or acquired chem-
oresistance, gemcitabine treatment has a marginal
survival benefit and yields an objective tumor response
rate of < 10% [5,6].
Multiple lines of evidence suggest that aberrantly acti-
vated nuclear factor-kappa B (NF-κB) plays a major role in
metastasis, cell proliferation, angiogenesis, and chemo-
therapy resistance of several tumor types including pan-
creatic cancer [7-11]. Activated NF-κB has been observed
in pancreatic cancer cell lines and animal models of pan-
creatic cancer, as well as primary human pancreatic can-
cers [7,12,13].
The NF-κB family of transcription factors [p65, p50, p52,
RelB, and c-Rel] is involved in the activation of a broad
range of genes involved in inflammation, differentiation,
tumourigenesis, metastasis, embryonic development, and
apoptosis [11,12,14]. They are activated in response to
extracellular stimuli including inflammatory cytokines
and growth factors, which results in the phosphorylation
and subsequent degradation of the NF-κB inhibitor IκB.
Additional levels of NF-κB regulation include phosphor-
ylation of p65 at various sites, although these are less well
characterized. NF-κB target genes encode cytokines [IL-1,
IL-12, IL-2, IL-6, IL-8, IL-10, TNF-α, interferon-β], tran-
scription factors [c-Myc], inhibitors of apoptosis [Bcl-2,
Bcl-XL, XIAP, FLIP], mitogenic factors [cyclin D1], and cell
adhesion molecules [E-selectin, ICAM-1, VCAM-1] [15-
17]. Previous in vitro studies have shown that inhibition of
NF-κB using IκBα super-repressor or sulfasalizine
enhances the effect of chemotherapeutic agents in pancre-
atic cancer cell lines [18,19]. Furthermore, inhibition of
NF-κB by the natural compound curcumin was reported
to potentiate the antitumor activity of gemcitabine in an
orthotopic xenograft model of pancreatic cancer [20].
Together, these findings suggest that aberrant activation of
NF-κB leads to chemoresistance in pancreatic cancer, and
that inhibition of NF-κB sensitizes the treatment out-
come.
Glycogen synthase kinase-3 (GSK-3) is a constitutively
active serine-threonine kinase that can phosphorylate and
inactivate a broad range of substrates including glycogen
synthase, cyclin D1, Mcl-1, c-myc, c-jun, β-catenin, tau,
notch, and HIF-1 [21]. Mammalian GSK-3 exists as two
isoforms, α and β, with semi-redundant actions that are
ubiquitously expressed in tissues [21,22]. In vivo and in
vitro studies have shown that GSK-3 can phosphorylate
and regulate NF-κB in a dual mode. The p65 subunit of
NF-κB has been reported to be phosphorylated by GSK-3
at serine 468 resulting in its decreased activity [23]. None-
theless, mice engineered to lack both GSK-3β alleles are
sensitive to TNF-α and die in late gestation due to massive
liver apoptosis; a phenotype similar to mice lacking p65
subunit of NF-κB or IKKβ [24,25]. Hepatocytes pretreated
with a GSK-3 inhibitor LiCl, were also shown to have
lower NF-κB activity, as measured by NF-κB dependent
luciferase assay. Furthermore, mouse embryonic fibrob-
lasts (MEFs) deficient in both alleles of GSK-3β fail to acti-
vate NF-κB after treatment with TNF-α, when compared to
wild type MEF [26]. Pharmacological or siRNA mediated
inhibition of GSK-3β has been shown to reduce NF-κB
mediated gene transcription and inhibit the growth of
cancers that show high NF-κB activity including pancre-
atic cancer [8,27,28]. These results point to a possible role
for GSK-3 in the maintenance of high NF-κB activity in
cancer cells. Since aberrant NF-κB activation has been
linked to drug resistance in pancreatic cancer, we tested
the hypothesis that reduction of NF-κB activity through
GSK-3 inhibition sensitizes pancreatic cancer cells to
chemotherapy.
Methods
Reagents and antibodies
Curcumin (Diferulylmethane, 80% pure; 98% curcumin-
oid content), was obtained from Sigma-Aldrich Canada
Ltd. (Oakville, Ontario, Canada), and GSK-3 Inhibitor
VIII [AR-A014418 (AR-18)] was obtained from CALBIO-
CHEM®, EMD Biosciences, Inc. (San Diego, CA). Both
agents were dissolved in DMSO and aliquots stored at -
20°C. Gemcitabine from Eli Lilly (Indianapolis, IN) was
freshly prepared as 10 mM stock in sterile PBS on the day
of use.
Rabbit polyclonal antibodies against XIAP, β-catenin, and
Bcl-XL were purchased from Cell Signaling Technology
(Danvers, MA). Rabbit monoclonal cyclin D1 antibody
was obtained from Lab Vision Corp. (Fremont, CA). A
mouse monoclonal antibody against GSK-3 α/β was
obtained from Biosource Inc. (Camarillo, CA). Anti-rab-
bit and anti-mouse horseradish peroxidase linked IgG
antibodies, were from Amersham Biosciences (Bucking-
hamshire, United Kingdom). Recombinant Human TNF-
α/TNFSF1A was purchased from R&D Systems (Minneap-
olis, MN)
Cell lines and media
The pancreatic cancer cell lines BxPC-3, MIA PaCa-2,
PANC-1, and HPAC were obtained from the American
Type Culture Collection (Rockville, MD), and PK-1 andBMC Cancer 2009, 9:132 http://www.biomedcentral.com/1471-2407/9/132
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PK-8 were from Dr. Masao Kobari (Sendai, Japan). BxPC-
3, PK-1, and PK-8 cell lines were cultured in RPMI 1640.
PANC-1 and MIA PaCa-2 cell lines were cultured in Dul-
becco Eagles medium. HPAC cells were cultured in HAM
F-12. All the media for cell culture were supplemented
with 10% fetal bovine serum (FBS), 100 units/mL penicil-
lin and 100 μg/mL streptomycin, and cells were grown at
37°C and 5% CO2 in air. Additional 2.5% horse serum
was added to the media growing MIA PaCa-2 cells.
Cell treatments, lysate preparation, and immunoblotting
Cells grown at 60% to 70% confluency were exposed to
different doses of AR-18 (0–50 μM), or lithium chloride
(LiCl) (0–50 mM), potassium chloride (KCl) (10 mM), or
solvent control, and incubated at 37°C in a CO2 incuba-
tor. After 48 h, the cells were lysed using RIPA buffer [20
mM Tris (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% Na
deoxycholate, 0.1% SDS, and 1 mM EDTA supplemented
with 1 mM Na3VO4, protease inhibitor cocktail (Roche
Diagnostics) and a serine/threonine-phosphatase inhibi-
tor cocktail 1 (Sigma-Aldrich). Alternatively, drug treated
cells were lysed and fractionated to separate the cytoplas-
mic content using hypotonic lysis buffer [50 mM Tris (pH
7.4), 1 mM EDTA, 10 mM NaF, 1 mM Na3VO4 and sup-
plemented with protease inhibitor cocktail (Roche Diag-
nostics) and serine/threonine-phosphatase inhibitor
cocktail 1 (Sigma-Aldrich)]. The protein content of the
supernatants was measured using bicinchoninic acid pro-
tein assay from Pierce PerBio (Rockford, IL) and twenty
five micrograms of the lysates were resolved on 8% or
10% SDS-PAGE gels. The resolved proteins were trans-
ferred onto polyvinylidene difluoride membranes (Milli-
pore, Bedford, MA), blocked with 5% non-fat milk, and
probed with the appropriate antibodies according to the
manufacturer's recommendation. The blots were washed,
and exposed to the appropriate HRP-conjugated second-
ary antibodies for 1 h at room temperature. Detection was
done using SuperSignal® West Pico from Pierce BioLynx
Inc. (Brockville, Ontario, Canada) reagent or enhanced
chemiluminescence plus (ECL Plus) kit (Amersham Bio-
sciences). Cytoplasmic lysates were used for detection of
β-catenin, whereas the rest of the proteins were detected
using the RIPA lysates. Blotting for α-tubulin from Onco-
gene Research Products, Calbiochem, (San Diego, CA) or
β-actin from Abcam Antibodis, Inc., (Cambridge, MA)
were used to control for protein loading.
Proliferation assay
The effect of AR-18, gemcitabine, and curcumin on cell
proliferation was determined by the Sulphorhodamine B
(SRB) dye (Molecular Probes, Eugene, OR) binding assay
as described previously [29]. Briefly, 5,000 cells per well
were seeded in 96-well plates, incubated in a CO2 incuba-
tor overnight at 37°C, and then treated with different
doses of curcumin (0–50 μM), AR-18 (0–50 μM) or gem-
citabine (0–1 μM) alone or in combination (i.e. concur-
rent or sequential) in triplicates for 24, 48, and 72 h. The
cells were then fixed using 10% (v/v) trichloroacetic acid
for 1 h at 4°C, washed extensively with water, stained with
0.4% SRB dissolved in 1% (v/v) acetic acid in water rea-
gent for 30 minutes at room temperature, and then
washed, and 10 mM unbuffered Tris was added to each
well. The absorbance was measured at 570 nm using a
Multiscan 96-well plate reader from Thermo Electron
Corp. (Milford, MA). This experiment was repeated three
times in six replicates.
Transient transfection and luciferase assay
PANC-1, MIA PaCa-2, PK-1, and PK-8 cells were seeded in
12-well plates (130,000 per well) in antibiotic-free
medium containing 10% FBS. The cells were incubated in
a CO2 incubator overnight at 37°C prior to transfection
using Lipofectamine 2000 from Invitrogen Life Technolo-
gies,(Carlsbad, CA) as recommended by the manufacture.
Briefly, 0.5 μg/well TA-LUC NF-κB (from Dr. T. Pawson,
Samuel Lunenfeld Research Institute, University of
Toronto), and 0.05 μg/well β-gal CMV (from Dr. W.C.
Yeh, Ontario Cancer Institute, University of Toronto)
were co-transfected to the cells. After 16 h, the medium
was changed and the cells were incubated with AR-18 (50
μM), gemcitabine (10 μM), or curcumin (50 μM) alone or
in combination for 8 h. TNF-α (30 ng/mL) was added to
the cells 4 h prior to cell lysis. Control cells were trans-
fected with the plasmids, but did not receive any drug
treatments. Luciferase activity was measured by using the
Dual-Light® System luciferase assay from Applied Biosys-
tems (Bedford, MA) according to the manufacturer's pro-
tocol. The luminometer used was Luminoskan Ascent
from ThermoLab Systems (Franklin, MA). The results
were normalized to the values read for β-galactosidase
activity. All experiments were performed in triplicate and
were repeated four times.
Genetic knockdown of GSK-3
PANC-1 cells were transfected using a reverse transfection
protocol. Briefly, the cells were seeded at 300,000 cells per
well in 6-well plates, then placed in a CO2 incubator at
37°C for 1 h prior to transfection with either silencer neg-
ative control siRNA or anti-GSK-3β from Applied Biosys-
tems, Ambion Inc. (Bedford, MA), or anti-GSK-3α
[Hs_GSK3A_5_HO Validated] from Qiagen, Inc. (Missis-
sauga, Ontario, Canada) or both by using Hiperfect trans-
fection reagent from Qiagen Inc. according to the
manufacturer's protocol. After 72 h, the cells were lysed
using RIPA or hypotonic lysis buffers and the proteins
present in cell lysates were resolved in SDS-PAGE. Prelim-
inary experiments showed that the concentrations of
siRNA required achieving >80% knockdown of GSK3α
and GSK3β were 10 nM and 80 nM, respectively. These
concentrations were used in all the studies.BMC Cancer 2009, 9:132 http://www.biomedcentral.com/1471-2407/9/132
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To combine the luciferase assay with genetic knockdown
of GSK-3, 24 h after siRNA transfection, the medium was
changed and the cells were subjected to co-transfection
with TA-LUC NF-κB and β-gal CMV as previously
described. After 24 h exposure, the medium was changed
and the cells were incubated for 48 h prior to exposure to
rather TNF-α (30 ng/mL, 4 h) or gemcitabine (10 μM, 8
h). Subsequently, the cells were lysed and the whole cell
lysates were used for luciferase assay as described above.
Clonogenic assay
The effect of AR-18 and of gemcitabine on survival of
PANC-1 and BxPC-3 cells was further investigated by a
colony-forming assay as described by Wu et al. [30]. In
brief, exponentially growing cells were treated with either
gemcitabine (0.001–10 μM), AR-18 (10–50 μM), or both
for 24 h. The cells were then trypsinized and washed twice
with PBS to remove the remaining drug, counted, and
then seeded in 10× and 5× serial dilutions for PANC-1
and BxPC-3 cells respectively. The plates were incubated
for 16 days at 37°C in a CO2 incubator at 90% humidity.
The plates were then stained with methylene blue from
Fischer Scientific, (Ottawa, ON) and colonies were
counted. The experiments were performed in triplicates,
and at least three times for each cell line.
Statistical analysis
All the statistical analysis was performed by the help of
"R" software (Hornik et al.; http://www.r-project.org). To
investigate the possible synergistic effect of combining
two agents, the interaction between the two drug treat-
ments was tested by fitting it into a model that considers
the fact that some experiments were not performed at the
same time. The values of optical density (for SRB), colony
count (clonogenic assay), or luciferase unit (luciferase
assay) were log transformed to stabilize the variance of the
residuals. The resulting values were analysed by compar-
ing between different concentrations of each drug using
linear regression models. A drug interaction was consid-
ered synergistic when the effect of the drug combination
was significantly greater than the sum of the effects of
both drugs, and sub-additive when it was less than that.
Results
Proliferation and colony-forming capacity of pancreatic 
cancer cells is decreased after pharmacological inhibition 
of GSK-3
Consistent with previous reports [28], treatment of
PANC-1 and BxPC-3 cells with the GSK-3 inhibitor AR-18
caused a growth inhibitory effect in a dose- and time-
dependent manner. Depending on the duration of expo-
sure, the IC50 values ranged from as low as 20 μM to as
high as 65 μM. After 48 h exposure, the (IC50) of AR-18
was approximately 30 μM for both cell lines (Fig. 1A). A
range of AR-18 doses below and above this range was used
for all our experiments, which is in line with previous
reports in pancreatic cancer cells [28]. We next tested AR-
18 sensitivity against a panel of four additional pancreatic
cancer cell lines. As shown in Fig. 1B, AR-18 potently
reduced cell proliferation of all six pancreatic cancer cell
lines tested in a dose- and time-dependent manner.
In order to determine whether GSK-3 is required for clo-
nogenic survival of pancreatic cancer cells, exponentially
growing PANC-1, and BxPC-3 cells were exposed to vary-
ing doses of AR-18 (10–50 μM) for 24 h. The number of
colony-forming cells was reduced in a concentration-
dependent manner by AR-18 (Fig 1C), and at 50 μM AR-
Inhibition of GSK-3 decreases proliferation and clonogenic  survival of pancreatic cancer cells in a dose- and time- dependent manner Figure 1
Inhibition of GSK-3 decreases proliferation and clo-
nogenic survival of pancreatic cancer cells in a dose- 
and time-dependent manner. A. Effects of AR-18 (μM) 
on the growth inhibition of BxPC-3 and PANC-1 cells after 
24, 48, and 72 h of drug exposure measured by SRB assay. 
Each point signifies mean from three experiments, each 
including six replicates; error bars = ± SEM. The results are 
relative to untreated control. B. Growth inhibitory effect of 
AR-18 (μM) against six pancreatic cancer cell lines after 
exposure for 24, 48, and 72 h, measured by SRB assay. Each 
point signifies mean from three separate experiments, each 
including six replicates; error bars = ± SEM. The results are 
relative to untreated control. C. Effects of AR-18 on the 
number of colony-forming PANC-1 and BxPC-3 cells after 
drug exposure for 24 h. Control cells were given vehicle 
solution. Each point represents mean for four experiments, 
each containing three replicates; error bars = ± SEM. The 
results are relative to untreated control.
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18 the number of colony-forming PANC-1 and BxPC-3
cells were 0.055 ± 0.02 and 0.022 ± 0.006, respectively
when compared with untreated controls.
GSK-3 mediates NF-κB activation in pancreatic cancer 
cells
Recent evidence suggests that GSK-3 is a positive regulator
of NF-κB [26-28,31]. To test this, we first treated PANC-1
and BxPC-3 cells with increasing concentrations of AR-18
for 48 h and examined effects on cytoplasmic β-catenin,
which is negatively regulated by GSK-3 via the Wnt path-
way. Inhibition of GSK-3 with increasing doses of AR-18
resulted in a dose-dependent increase in the levels of cyto-
plasmic β-catenin with ~twofold increase at 50 μM AR-18,
when compared to control, which is the expected pharma-
codynamic effect (Fig. 2A). We next examined the effects
of AR-18 treatment on the expression of the NF-κB target
genes XIAP, cyclin D1, and Bcl-XL, and found that expres-
sion of these proteins was also reduced significantly in a
dose-dependent manner (Fig 2A–B). Similar results were
obtained using the unrelated GSK3 inhibitor, LiCl (Addi-
tional file 1).
To test if GSK-3 inhibition could impact basal NF-κB
activity in pancreatic cancer cells, PANC-1, MIA PaCa-2,
PK-1 and PK-8 cells were transfected with TA-LUC NF-κB
and treated with AR-18. In all cell lines AR-18 treatment
(50 μM, 8 h) significantly decreased basal NF-κB activity
when compared to untreated control (Fig. 2C, and data
not shown).
Since TNF-α induced NF-κB activity was reported to be
inhibited in MEFs genetically lacking the GSK-3β isoform
[26], we tested this by treating PANC-1 and MIA PaCa-2
cells with TNF-α(30 ng/ml, 4 h) in the presence or
absence of AR-18. In both cell lines, TNF-α induced NF-κB
luciferase activity above background by ~2.5–fold in con-
trol cells, whereas in cells pretreated with AR-18 the levels
of NF-κB luciferase remained lower than baseline, and
were not significantly different from those seen with AR-
18 alone (Fig. 2C). Together, these findings support the
idea that GSK-3 positively regulates basal NF-κB activity
[28] and that inhibition of GSK-3 abrogates the activation
of NF-κB by TNF-α.
Genetic knockdown of GSK-3 abolishes NF-κB activity in 
pancreatic cancer cells
Previous work suggests that inhibitors such as LiCl and
AR-18 likely do not distinguish between the two GSK-3
isoforms [32]. To determine the effect of GSK-3 isoforms
on NF-κB target gene expression in pancreatic cancer cells,
we genetically depleted the expression of GSK-3α and
GSK3β, alone or in combination, in PANC-1 cells using
RNA interference. Following a 3-day exposure to GSK-3
specific siRNAs, immunoblotting showed >80% reduc-
tion in the expression levels of the corresponding GSK-3
isoforms when compared to untransfected or scrambled
siRNA transfected controls (Fig. 3A). Depletion of either
GSK-3α or β isoforms had minor effects on expression lev-
els of Bcl-XL, XIAP, cyclin-D1, and β-catenin, with a
Inhibition of GSK-3 disrupts NF-κB activity in pancreatic can- cer cells in a dose-dependent manner Figure 2
Inhibition of GSK-3 disrupts NF-κB activity in pancre-
atic cancer cells in a dose-dependent manner. A-B. 
Western blot analysis of expression of β-catenin and NF-κB 
target genes: XIAP, BcL-XL, and cyclin D1, in PANC-1 and 
BxPC-3 cell lines after exposure to AR-18 for 48 h. The 
change in the expression level of the proteins is compared 
against untreated or vehicle treated controls. Increase in 
cytosolic β-catenin level indicates GSK-3 inhibition. Both α-
tubulin and β-actin were used as loading controls. C. Effect of 
GSK-3 disruption on basal and TNF-α induced NF-κB activity 
measured by luciferase reporter assay. PANC-1 and MIA 
PaCa-2 cells were exposed to AR-18 (50 μM, 8 h), TNF-α(30 
ng/mL, 4 h), or both after co-transfection with TA-LUC NF-
κB reporter and β-gal (internal control) constructs. The nor-
malized values are relative to the untreated control (indicat-
ing basal level of NF-κB activity) which is represented by 
dotted line. Each column represents mean for at least four 
separate experiments, each with three replicates; error bars 
= ± SEM. (*) significant: (p < 0.0003) when compared to 
untreated control. (**) significant: (p < 0.0001) when com-
pared to TNF-α treatment.
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greater effect shown by GSK-3β knockdown. However,
consistent with pharmacological inhibition of GSK-3
using AR-18, simultaneous knockdown of both GSK-3
isoforms in PANC-1 cells led to a significantly greater
effects on β-catenin, Bcl-XL, XIAP, and cyclin-D1 expres-
sion levels when compared to the single isoform knock-
downs (Fig 3A).
To further test the effect of GSK-3 isoforms knockdown on
basal NF-κB activity, we measured the level of NF-κB luci-
ferase activity in knockdowns of PANC-1 cells. Inhibition
of GSK-3α, β, or double knockdown of both GSK-3 iso-
forms significantly decreased the basal NF-κB activity (Fig.
3B); with greater effect exerted by genetic depletion of
GSK-3β and the double knockdown (Fig. 3B). While TNF-
α treatment induced >2.5 fold increase in non-specific
(scrambled) siRNA treated cells, knockdown of either
GSK-3 isoform resulted in a significant decrease in basal
NF-κB luciferase activity and attenuated the effect of TNF-
α, although these effects were greater with GSK3β knock-
down. A large effect was seen when both isoforms were
knocked down (Fig 3B), suggesting that whereas GSK3α is
able to stimulate NF-κB activity, this is mediated princi-
pally by GSK-3β.
GSK-3 inhibition does not enhance the anti-tumor effects 
of gemcitabine in pancreatic cancer in vitro
Using the SRB cell proliferation assay, the growth of BxPC-
3 and MIA PaCa-2 cell lines was measured after 24, 48,
and 72 h of exposure to a range of concentrations of either
AR-18, gemcitabine, or a concurrent combination of both
drugs; using either a fixed ratio of 200:1 AR-18 to gemcit-
abine, or variable doses of both drugs. AR-18 produced a
steep dose-response over the 10–50 μM concentration
range and this effect increased with the duration of expo-
sure (Fig 4; 24 and 72 h data not shown). In contrast, the
gemcitabine dose-response showed a plateau at low con-
centrations, and sensitivity was greatly influenced by the
duration of drug exposure, consistent with the cell cycle
phase-specificity of this agent.
Contrary to our hypothesis, combining both drugs either
in a fixed ratio or variable doses was not synergistic
against BxPC-3 or MIA PaCa-2 cells when compared to the
single agents, across a wide range of concentrations and
treatment times (Fig. 4A; 24 and 72 h data not shown).
We also treated the four other pancreatic cancer cell lines
using variable doses of both drugs for different time
points. As seen in Fig 4B, with the exception of PANC-1
that showed a statistically-significant synergistic effect at
some dose levels (Fig. 4B; 24 and 72 h data not shown),
the drug combination was either sub-additive or even
Genetic knockdown of GSK-3 by siRNA results in disruption  of NF-κB activity Figure 3
Genetic knockdown of GSK-3 by siRNA results in dis-
ruption of NF-κB activity. A. Western blot analysis of 
expression of NF-κB target genes XIAP, BcL-XL, and cyclin 
D1 in PANC-1 cells after transient knockdown of GSK-3 iso-
forms; α(10 nM siRNA), β (80 nM siRNA) or both. Expres-
sion level of total GSK-3 α or β isoforms confirms the 
genetic knockdown of the specified gene. Increased cytosolic 
β-catenin expression confirms GSK-3 inhibition. The change 
in the expression level of the proteins is compared against 
untreated or scrambled siRNA (negative control) treated 
controls. α-tubulin is used as loading control. B. Effect of 
genetic disruption of GSK-3 on basal and TNF-α induced NF-
κB activity measured by luciferase reporter assay. PANC-1 
cells were genetically knocked down for GSK-3 isforms α, β 
or both, and subsequently were co-transfected with TA-LUC 
NF-κB and β-gal (internal control) constructs. The cells were 
then exposed to TNF-α(30 ng/mL, 4 h). The normalized val-
ues are relative to the untreated control which is repre-
sented by dotted line (indicating basal level of NF-κB 
activity). Scrambled siRNA with or without TNF-α treatment 
is used as control. Each column represents mean for at least 
four experiments, each with three replicates; error bars = ± 
SEM. (*) significant: (p < 0.0005) when compared to 
untreated control. (**) significant: (p < 0.0001) when com-
pared to TNF-α treatment. Western blot analysis of expres-
sion of GSK-3α and β isoforms in the above cells confirms 
successful knock down of the target genes.
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antagonistic. Because of the possibility that AR-18 might
be antagonizing the effects of gemcitabine by reducing
movement through S-phase, we also tested if prior expo-
sure to gemcitabine sensitized to AR-18 but did not iden-
tify positive drug interaction under any of the conditions
used.
To further investigate the interactions of AR-18 and gem-
citabine, we tested the effect on the colony-forming capac-
ity of PANC-1 and BxPC-3 cell lines. The cells were
exposed to doses of AR-18, gemcitabine or their combina-
tion similar to those used for the SRB assay. No evidence
of drug synergy was observed across a wide range of drug
concentrations (Fig 4C).
Since treatment with gemcitabine was reported to cause
NF-κB activation in pancreatic cancer cells in vitro [7], we
tested if this effect is sensitive to GSK-3 inhibition. Conse-
quently, TA-LUC NF-κB transfected PANC-1, MIA PaCa-2,
PK-1, and PK-8 cells were exposed to gemcitabine (10
μM), AR-18 (50 μM), or both for 8 h and NF-κB activity
was examined. We found a moderate increase in NF-κB
activity effect in PANC-1 cells that appeared to be depend-
ent on the experimental conditions (Fig. 5A and 5B). No
significant increase was seen in MIA PaCa-2, PK1, and PK-
8 cells (Fig. 5A, and data not shown). Although AR-18 sig-
nificantly reduced basal NF-κB activity in all the cell lines,
the combination of gemcitabine and AR-18 produced
similar effects on the NF-κB reporter to those seen with
single agent AR-18 (Fig. 5A, and data not shown). Further-
more, when we combined gemcitabine with transient
knockdown of GSK-3 isoforms in PANC-1 cells, there was
no increase in NF-κB activity (Fig. 5B).
Similar to AR-18, curcumin inhibits NF-κB activity, but fails 
to sensitize pancreatic cancer cells to gemcitabine effect in 
vitro
Since GSK-3 could have both pro- and anti-apoptosis
effects, we considered that the lack of sensitization to
gemcitabine using AR-18 might be explained by the effect
of GSK-3 on targets other than NF-κB that could poten-
tially modify chemotherapy sensitivity. To address this,
we compared the effects using curcumin, which inhibits
NF-κB through different mechanisms. Similar to previous
reports and consistent with our observations using AR-18,
both PANC-1 and MIA PaCa-2 cells showed a significant
decrease in basal as well as TNF-α induced NF-κB activity
after exposure to curcumin (50 μM) for 8 h (Fig. 6A). We
then tested for synergism by exposing PANC-1 and MIA
PaCa-2 cells to various doses of curcumin, gemcitabine, or
their combination in doses similar to those used by Kun-
numakkara et al. [20]. Consistent with their findings, 48 h
exposure to curcumin had a significant growth inhibitory
effect on these cell lines measured by SRB assay (Fig. 6B).
However, as seen in Fig 6B and similar to our results using
AR-18, NF-κB inhibition by curcumin did not sensitize
the pancreatic cancer cells to gemcitabine. Likewise, the
effect of curcumin down-regulating NF-κB luciferase activ-
ity was not significantly altered by combined treatment
with gemcitabine (Fig. 6C).
Effects of AR-18 on gemcitabine sensitivity Figure 4
Effects of AR-18 on gemcitabine sensitivity. A. Growth 
inhibitory effect of AR-18 (2.5–50 μM), gemcitabine (0.05–1.0 
μM), and their combination in a 200:1 AR-18 to Gemcitabine 
ratio was measured by the SRB proliferation assay in MIA 
PaCa-2 and BxPC-3 after 48 h of exposure. Each point repre-
sents mean from three experiments, each with six replicates; 
error bars = ± SEM. Gem: gemcitabine. The results are indi-
cated by relative cell proliferation as a percentage of solvent 
control. B. Growth inhibitory effect of AR-18 (10–50 μM), 
gemcitabine (0.001–1.0 μM), and their combination was 
measured by the SRB proliferation assay in PANC-1, HPAC, 
PK-1, and PK-8 cell lines after 48 h of exposure. Each point 
represents mean from three separate experiments, each with 
six replicates; error bars = ± SEM. Gem: gemcitabine. The 
results are indicated by relative cell proliferation as a per-
centage of solvent control. C. Effect of AR-18 (10–50 μM), 
gemcitabine (0.001–1.0 μM), and their combination on col-
ony-forming capacity of PANC-1 and BxPC-3 cells was meas-
ured by colonogenic assay. Control cells were given vehicle 
solution. Means for four separate experiments, each with 
three replicates; error bars = ± SEM. Gem: gemcitabine. The 
results are relative to vehicle treated control.
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Effects of gemcitabine combined with GSK-3 inhibition on  NF-κB Figure 5
Effects of gemcitabine combined with GSK-3 inhibi-
tion on NF-κB. A. Effect of AR-18 (50 μM, 8 h), gemcitab-
ine (10 μM, 8 h), and their combination measured by NF-κB 
luciferase reporter assay. PANC-1 and MIA PaCa-2 cells 
were co-transfected with TA-LUC NF-κB reporter con-
struct and β-gal (internal control) and then exposed to AR-
18, gemcitabine or both. The normalized values are relative 
to the untreated control which is represented by dotted line 
(indicating basal level of NF-κB activity). Each column repre-
sents the mean for at least four experiments, each with three 
replicates; error bars = ± SEM. (*) significant: (p < 0.0003) 
when compared to untreated control. Gem: gemcitabine. B. 
Effect of genetic disruption of GSK-3 and its combination 
with gemcitabine on NF-κB activity measured by luciferase 
reporter assay. PANC-1 cells were genetically knocked 
down for GSK-3 isforms α(10 nM), β (80 nM) or both, and 
subsequently were co-transfected with TA-LUC NF-κB and 
β-gal (internal control) constructs. The genetically treated or 
untreated cells were then exposed to gemcitabine (10 μM, 8 
h). The normalized values are relative to the untreated con-
trol which is represented by dotted line (indicating basal level 
of NF-κB activity). Each column represents the mean for at 
least four experiments, each with three replicates; error bars 
= ± SEM. (*) significant: (p = 0.08) when compared to 
untreated control. (**) significant: (p < 0.0005) when com-
pared to untreated control. Gem: gemcitabine. Western blot 
analysis of expression of GSK-3α and β isoforms in the above 
cells confirms successful knock down of the target genes.
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NF-κB inhibition by curcumin does not increase sensitivity to  gemcitabine in pancreatic cancer cells Figure 6
NF-κB inhibition by curcumin does not increase sen-
sitivity to gemcitabine in pancreatic cancer cells. A. 
Effect of curcumin on basal and TNF-α induced NF-κB activ-
ity measured by luciferase reporter assay. PANC-1 and MIA 
PaCa-2 cells were exposed to curcumin (50 μM, 8 h), TNF-
α(30 ng/mL, 4 h), or both after co-transfection with TA-LUC 
NF-κB reporter and β-gal (internal control) constructs. The 
normalized values are relative to the untreated control 
which is represented by dotted line (indicating basal level of 
NF-κB activity). Each column represents the mean for at 
least four separate experiments, each with three replicates; 
error bars = ± SEM. (*) significant: (p < 0.001) when com-
pared to untreated control. (**) significant: (p < 0.0001) 
when compared to TNF-α treatment. Cur: curcumin, 
Gem:gemcitabine. B. Growth inhibitory effect of curcumin 
(2.5–50 μM), gemcitabine (0.05–1.0 μM), and their combina-
tion in a 200:1 (curcumin to gemcitabine) ratio was measured 
by the SRB proliferation assay in MIA PaCa-2 and PANC-1 
after 48 h of exposure. Each point represents the mean from 
three separate experiments, each with six replicates; error 
bars = ± SEM. Cur: curcumin, Gem: gemcitabine. The results 
are indicated by relative cell proliferation as a percentage of 
solvent control. C. Effect of curcumin (50 μM, 8 h), gemcit-
abine (10 μM, 8 h), and their combination measured by luci-
ferase reporter assay. PANC-1 and MIA PaCa-2 cells were 
co-transfected with TA-LUC NF-κB reporter construct and 
β-gal (internal control) and then exposed to curcumin, gem-
citabine or both. The normalized values are relative to the 
untreated control which is represented by dotted line (indi-
cating basal level of NF-κB activity). Each column shows the 
mean for at least four experiments, each with three repli-
cates; error bars = ± SEM. (*) significant: (p < 0.001) when 
compared to untreated control. Cur: curcumin, Gem: gem-
citabine.
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Discussion
Chemotherapy resistance of pancreatic cancer has been
previously associated with hyperactivity of NF-κB
[7,11,19,33]. The discovery that GSK-3 regulates NF-κB
[26], and that its inhibition has anti-inflammatory and
growth inhibitory effects, holds promise to resolve the
problem of drug resistance in cancers with inflammatory
origin including pancreatic cancer [26,28,34]. In this
paper, using a panel of six genetically distinct pancreatic
cancer cell lines we confirmed previous reports that phar-
macological inhibition of GSK-3 suppresses NF-κB tran-
scriptional activity and is toxic to pancreatic cancer cells in
a dose- and time-dependent manner [28]. We also show
for the first time that GSK-3 inhibition potently reduces
the clonogenic survival of pancreatic cancer cells. How-
ever, contrary to our hypothesis GSK-3/NF-κB inhibition
did not sensitize to gemcitabine chemotherapy.
GSK-3 is a kinase involved in many cellular processes
including energy metabolism, transcriptional regulation,
cell adhesion, and protein turnover [35,36]. This com-
plexity of action results in a potential for GSK-3 to exert
both pro- and anti-apoptotic effects that appears to be
cell- and context-dependent [37]. The anti-apoptotic
activity of GSK-3 has been attributed in part to the stimu-
lation of NF-κB activity through an unknown mechanism,
as shown by this study and others [26,28,31]. It has been
previously shown that β-catenin has inhibitory effects on
NF-κB [38], which could explain the effects of GSK-3 inhi-
bition since this results in the accumulation of β-catenin.
Although the accumulation of β-catenin could potentially
be cancer-promoting, this did not rescue pancreatic cells
from death due to lack of NF-κB activity, further support-
ing the importance of NF-κB activity in maintaining the
survival of these cells, whereas Wnt/β-catenin appears to
play a less prominent role in pancreatic cancer develop-
ment [34]. The above findings in conjunction with others
[26,28,39] lend support to a positive role for GSK-3 activ-
ity in the regulation of NF-κB, rather than inhibition
through S468 phosphorylation as has been described in
other systems [23].
Since GSK-3 inhibitors including Wnt, LiCl, and AR-18
likely do not discriminate between GSK-3 α and β iso-
forms [26,40], and given that functional redundancy of
GSK-3 isoforms in the context of Wnt/β-catenin signaling
has been previously described in mouse embryonic stem
cells [22], we investigated whether NF-κB regulation by
GSK-3 was isoform-specific in pancreatic cancer cells.
Transient genetic knockdown of GSK-3α had a minor
impact on β-catenin, cyclin D1 and XIAP expression when
compared to GSK-3β knockdown, whereas GSK-3α/β
double knockdown demonstrated the greatest effect. Sim-
ilarly, transient knockdown of either GSK-3α or GSK-3β
significantly reduced both the basal as well as the TNF-α
induced NF-κB activity of PANC-1 cells, although GSK-3β
knockdown exerted the greater effect and the double
knockdown of both isoforms was the most effective. Col-
lectively, these findings suggest that although NF-κB activ-
ity in pancreatic cancer is responsive to both GSK-3
isoforms, GSK-3β is the major regulator. Our finding of
the differential effects of GSK-3 isoforms is in agreement
with the previously proposed functional redundancy of
GSK-3 isoforms [22], and also confirms the importance of
GSK-3β in NF-κB regulation [26,41]. Furthermore, our
observations also raise the possibility of NF-κB cross-reg-
ulation by GSK-3 isoforms in pancreatic cancer. This phe-
nomenon could have important implications with
regards to the development of isoform specific GSK-3
inhibitors, and further work in this area appears indicated.
Since GSK-3 inhibition efficiently suppresses NF-κB in
pancreatic cancer cells, and downregulates NF-κB targets
associated with chemotherapy resistance such as XIAP and
Bcl-XL, it seemed reasonable to predict that this would
also sensitize these cells to gemcitabine. In all six cell lines
tested, treatment with AR-18 as a single agent was growth
inhibitory in a dose- and time-dependent manner, similar
to a previous report [28]. However, with the exception of
PANC-1 the combination with gemcitabine was not syn-
ergistic. In fact, across a wide range of conditions and drug
combinations, the interactions ranged from additive to
antagonistic effects. Similar additive or antagonistic
effects were observed in PANC-1 or BxPC-3 cells using clo-
nogenic survival as the endpoint.
The lack of sensitization to gemcitabine by GSK-3 inhibi-
tion in pancreatic cancer might be due to number of rea-
sons: 1) Some of the proteins targeted by GSK-3 for
proteasomal degradation, including Mcl-1, β-catenin, and
cdc25 [42-44], have cancer-promoting effects. Conse-
quently, GSK-3 inhibition might have adverse effects by
stabilizing these proteins; 2) GSK-3 inhibition is reported
to confer resistance to chemotherapy through suppression
of death receptor-mediated apoptosis [45,46]; 3) Gemcit-
abine treatment has been previously reported to induce
NF-κB activity in vitro [7], and this effect might counteract
the inhibition of NF-κB seen following treatment with AR-
18. However, this appears not to be the case under the
experimental conditions used, since in the present study
the increase in NF-κB activity following gemcitabine expo-
sure was modest and cell line dependent, and effectively
inhibited by AR-18 or GSK-3 knockdown; 4) It is also pos-
sible that although NF-κB is hyper-activated in pancreatic
cancer, it does not play a major role in gemcitabine resist-
ance, which is in line with some recent reports [47-49], 5)
We also considered that as gemcitabine cytotoxicity is cell
cycle dependent, GSK-3 inhibition might antagonize
gemcitabine by slowing entry into S-phase or causing cell
cycle arrest. However, DNA content analysis by flow
cytometry showed that the cell cycle effects of AR-18 were
relatively modest, which is in line with a previous reportBMC Cancer 2009, 9:132 http://www.biomedcentral.com/1471-2407/9/132
Page 10 of 12
(page number not for citation purposes)
that in contrast to some other GSK-3 inhibitors, AR-18 is
a relative weak inhibitor of cyclin-dependent kinases [50].
Furthermore, we did not observe increased sensitization
to the drug combination when cells were pre-exposed to
gemcitabine prior to the addition of AR-18 (data not
shown). Although the enhancement of gemcitabine toxic-
ity following GSK-3 inhibition appears to be modest in
vitro, we recognize that this does not exclude the potential
for positive drug interaction in vivo, and this remains to be
tested.
To investigate whether NF-κB inhibition by agents other
than GSK-3 inhibitors could potentiate gemcitabine sen-
sitivity, we tested the natural product curcumin. We found
that curcumin inhibited both constitutive and TNF-α-
induced NF-κB activity in PANC-1 and MIA PaCa-2 cells,
and was also toxic in a dose-and time-dependent manner,
which was consistent with previous reports [20,51]. How-
ever, in contrast to findings by Kunnumakkara et al., and
similar to our findings with AR-18, we did not observe
enhancement of gemcitabine toxicity by curcumin. Thus,
our findings do not support a role for NF-κB activity as a
significant mediator of gemcitabine resistance in pancre-
atic cancer, or the corollary that NF-κB inhibition is able
to overcome chemotherapy resistance. These results are
corroborated by a recent study in colon cancer cell lines,
where p65 overexpression could sensitize the cells to cur-
cumin effects [47], and by other reports suggesting that
NF-κB might function as a pro-apoptotic or a tumor sup-
pressor factor [47-49,52], depending on the nature of
apoptotic stimuli or the cell type.
Thus, although this work supports a model in which acti-
vated NF-κB is maintained by GSK-3 and promotes the
survival of pancreatic cancer cells, we suggest that the
major mechanisms of gemcitabine resistance are not
dependent on NF-κB. Alternative mechanisms include
alterations in drug uptake and metabolism, enhanced
DNA repair proficiency, or activation of survival by other
signaling pathways such as PI3-kinase/Akt. The exact role
of GSK-3 in the maintenance of pancreatic cancer, the dif-
ferential role of its isoforms in regulating NF-κB activity in
these cells, and the mechanisms or conditions through
which it maintains NF-κB activity remain unclear,
although recent work suggests an important role for GSK-
3 in the phosphorylation of IKK [39]. Furthermore, the
mechanisms of cell death following GSK-3 inhibition
appear not to be through classical apoptosis pathways as
we did not observe PARP cleavage or loss of mitochon-
drial membrane potential, and AR-18 treated cells could
not be rescued using the general caspase inhibitor zVAD
(fmk) (data not shown). In summary, this work supports
a potentially important role for GSK-3 inhibition in the
treatment of pancreatic cancer, but cautions that further
work examining the underlying mechanisms is needed for
this to be rationally exploited in the clinic.
Conclusion
Our observations suggest that although GSK-3 inhibition
does not significantly sensitize to the standard chemo-
therapy agent gemcitabine, yet it is a promising new
approach to the treatment of pancreatic cancer through
disruption of NF-κB. We also conclude that NF-κB is not
a key player in gemcitabine resistance of pancreatic can-
cer. Further work is needed to understand the mecha-
nisms of the anticancer effect of GSK-3 inhibition,
including the potential for rational combination with
other targeted agents for the treatment of pancreatic can-
cer.
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